University Health, University of Miami Health System
Welcome,         Profile    Billing    Logout  
 3 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kleiner, Gary
NCT05149300 / 2021-004590-30: COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

Recruiting
2a
28
US
casirivimab+imdevimab, REGN10933-10987, REGN-COV2, REGEN-COV™, RONAPREVE™
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals Inc
COVID-19
11/22
11/22
CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting
2
64
Canada, US
Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS
Michael Pulsipher, MD
SCID
08/26
08/26
NCT02915406: cliniMACs HUD for T Cell Depletion

No Longer Available
N/A
US
CliniMACs
University of Miami, Jackson Health System
x Linked Combined Immunodeficiency
 
 
Weisman, Alejandra
BEGIN, NCT04509050: Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

Recruiting
N/A
210
US
Ivacaftor or elexacaftor/tezacaftor/ivacaftor, Kalydeco or Trikafta, Vertex (VX)-770 or VX-445/VX-661/VX-770
Sonya Heltshe, Cystic Fibrosis Foundation, University of Washington, University of Alabama at Birmingham
Cystic Fibrosis
12/29
12/29

Download Options